서브메뉴
검색
상세정보
The role of angiotensinogen in atherosclerosis and obesity- [electronic resource]
The role of angiotensinogen in atherosclerosis and obesity- [electronic resource]
상세정보
- 자료유형
- 학위논문(국외)
- 자관 청구기호
- 기본표목-개인명
- 표제와 책임표시사항
- The role of angiotensinogen in atherosclerosis and obesity - [electronic resource] / Wu, Congqing.
- 발행, 배포, 간사 사항
- 발행, 배포, 간사 사항
- 형태사항
- 1 online resource(136 p)
- 일반주기
- Source: Dissertation Abstracts International, Volume: 78-02(E), Section: B.
- 일반주기
- Adviser: Alan Daugherty.
- 학위논문주기
- Thesis (Ph.D.)--University of Kentucky, 2014.
- 요약 등 주기
- 요약Angiotensinogen is the only known precursor in the renin-angiotensin system, a hormonal system best known as an essential regulator of blood pressure and fluid homeostasis. Angiotensinogen is sequentially cleaved by renin and angiotensin-converting enzyme to generate angiotensin II. As the major effector peptide, angiotensin II mainly function through angiotensin type 1 receptor.
- 요약 등 주기
- 요약Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and more recently renin inhibitors are widely known as the 3 classic renin-angiotensin system inhibitory drugs against hypertension and atherosclerosis. Here, we developed an array of regents to explore the effects of angiotensinogen inhibition. First, we demonstrated that genetic deficiency of angiotensinogen not only protected against hypercholesterolemia-induced atherosclerosis but also prevented diet-induced obesity. Then we found weekly intraperitoneal injection of antisense oligonucleotides against angiotensinogen remarkably surpressed body weight gain in mice fed a western diet, which was absent from classic renin-angiotensin system inhibition. The suppressed body weight gain was attributable to diminished body fat mass gain and enhanced energy expenditure. More excitingly, angiotensinogen antisense oligonucleotides regressed body weight gain on obese mice. Together, our findings revealed a unique feature of angiotensinogen inhibition beyond classic renin angiotensin inhibition and demonstrated therapeutic potentials of angiotensinogen antisense oligonucleotides against hypertension, atherosclerosis, and obesity.
- 요약 등 주기
- 요약We also developed an in vivo system to explore the functional consequences of disrupting a conserved Cys18-Cys137 disulfide bridge in angiotensinogen. The formation of this disulfide bridge could trigger conformational changes in angiotensinogen, thereby facilitating renin cleavage of angiotensinogen. It was predicted that the redox-sensitive disulfide bridge might change the efficiency of angiotensinogen/renin reaction to release angiotensin II, thus modulate angiotensin II-dependent functions. We determined effects of the presence and absence of the disulfide bridge on angiotensin II concentrations and responses in mice expressing either native angiotensinogen or Cys18Ser, Cys137Ser mutated angiotensinogen in liver via adeno-associated viral vectors. Contrary to the prediction, disruption of Cys18-Cys137 disulfide bridge in angiotensinogen had no discernible effects on angiotensin II production and angiotensin II-dependent functions in mice.
- 요약 등 주기
- 요약KEYWORDS: Angiotensinogen, atherosclerosis, obesity, disulfide bridge.
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 부출표목-단체명
- 기본자료저록
- Dissertation Abstracts International. 78-02B(E).
- 기본자료저록
- Dissertation Abstract International
- 전자적 위치 및 접속
- 원문정보보기
- 소장사항
-
20180515 2018
MARC
008180601s2014 us esm 001c eng■001MOKWON01260306
■00520180518093224
■007cr
■020 ▼a9781339988054
■035 ▼a(MiAaPQ)AAI10143593
■040 ▼aMiAaPQ▼cMiAaPQ
■090 ▼a전자도서(박사논문)
■1001 ▼aWu, Congqing.
■24514▼aThe role of angiotensinogen in atherosclerosis and obesity▼h[electronic resource]▼cWu, Congqing.
■260 ▼a[Sl]▼bUniversity of Kentucky▼c2014
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2014
■300 ▼a1 online resource(136 p)
■500 ▼aSource: Dissertation Abstracts International, Volume: 78-02(E), Section: B.
■500 ▼aAdviser: Alan Daugherty.
■5021 ▼aThesis (Ph.D.)--University of Kentucky, 2014.
■520 ▼aAngiotensinogen is the only known precursor in the renin-angiotensin system, a hormonal system best known as an essential regulator of blood pressure and fluid homeostasis. Angiotensinogen is sequentially cleaved by renin and angiotensin-converting enzyme to generate angiotensin II. As the major effector peptide, angiotensin II mainly function through angiotensin type 1 receptor.
■520 ▼aAngiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and more recently renin inhibitors are widely known as the 3 classic renin-angiotensin system inhibitory drugs against hypertension and atherosclerosis. Here, we developed an array of regents to explore the effects of angiotensinogen inhibition. First, we demonstrated that genetic deficiency of angiotensinogen not only protected against hypercholesterolemia-induced atherosclerosis but also prevented diet-induced obesity. Then we found weekly intraperitoneal injection of antisense oligonucleotides against angiotensinogen remarkably surpressed body weight gain in mice fed a western diet, which was absent from classic renin-angiotensin system inhibition. The suppressed body weight gain was attributable to diminished body fat mass gain and enhanced energy expenditure. More excitingly, angiotensinogen antisense oligonucleotides regressed body weight gain on obese mice. Together, our findings revealed a unique feature of angiotensinogen inhibition beyond classic renin angiotensin inhibition and demonstrated therapeutic potentials of angiotensinogen antisense oligonucleotides against hypertension, atherosclerosis, and obesity.
■520 ▼aWe also developed an in vivo system to explore the functional consequences of disrupting a conserved Cys18-Cys137 disulfide bridge in angiotensinogen. The formation of this disulfide bridge could trigger conformational changes in angiotensinogen, thereby facilitating renin cleavage of angiotensinogen. It was predicted that the redox-sensitive disulfide bridge might change the efficiency of angiotensinogen/renin reaction to release angiotensin II, thus modulate angiotensin II-dependent functions. We determined effects of the presence and absence of the disulfide bridge on angiotensin II concentrations and responses in mice expressing either native angiotensinogen or Cys18Ser, Cys137Ser mutated angiotensinogen in liver via adeno-associated viral vectors. Contrary to the prediction, disruption of Cys18-Cys137 disulfide bridge in angiotensinogen had no discernible effects on angiotensin II production and angiotensin II-dependent functions in mice.
■520 ▼aKEYWORDS: Angiotensinogen, atherosclerosis, obesity, disulfide bridge.
■590 ▼aSchool code: 0102.
■650 4▼aPathology
■650 4▼aPhysiology
■650 4▼aMolecular biology
■650 4▼aBiochemistry
■690 ▼a0571
■690 ▼a0719
■690 ▼a0307
■690 ▼a0487
■71020▼aUniversity of Kentucky.
■7730 ▼tDissertation Abstracts International▼g78-02B(E).
■773 ▼tDissertation Abstract International
■790 ▼a0102
■791 ▼aPh.D.
■792 ▼a2014
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T14821533▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
■980 ▼a20180515▼f2018
![The role of angiotensinogen in atherosclerosis and obesity - [electronic resource] / Wu, C...](/Sponge/Images/bookDefaults/DDbookdefaultsmall.png)


한글
ENG
日本
中文
Việt Nam